Repligen Corp.
(NASDAQ : RGEN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.81%53.550.9%$1397.05m
JNJJohnson & Johnson -0.02%179.430.7%$1295.65m
BMYBristol-Myers Squibb Co. -2.36%75.761.0%$1183.57m
MRKMerck & Co., Inc. 0.05%92.360.7%$1167.53m
ABBVAbbVie, Inc. -1.23%148.721.9%$1086.85m
LLYEli Lilly & Co. 1.66%318.661.1%$983.26m
AZNAstraZeneca Plc 0.80%67.241.0%$495.48m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.19%143.450.0%$493.51m
NVSNovartis AG -0.12%91.150.2%$259.53m
GSKGlaxoSmithKline Plc -1.10%43.930.2%$254.75m
VERUVeru, Inc. -0.91%12.530.0%$251.50m
HZNPHorizon Therapeutics Plc 3.39%93.675.4%$202.69m
SGENSeagen Inc. 3.06%142.695.7%$191.34m
NVONovo Nordisk A/S 0.65%107.290.1%$184.04m
VTRSViatris, Inc. 1.00%12.130.0%$166.92m

Company Profile

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration, Process Analytics, and Proteins. The Chromatography product includes a range of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The Process Analytics products complement and support filtration, chromatography and proteins in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins product franchise is represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.